NRX Pharmaceuticals Posts Q2 Loss, Reaffirms Going Concern Warning, and Ends Kadima Agreement
NRXP sits 96% above its 52-week low of $1.62.
Summary
NRX Pharmaceuticals reported a $16.5 million Q2 net loss, reiterated its going concern warning, and terminated the Kadima acquisition. The company also announced DARPA selection for a $11.5 million trial and positive FDA feedback on its ketamine ANDA.
Key Events · Earnings and Guidance · NRXP
-
Going Concern Warning Reiterated
Management concluded substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the issuance date, citing recurring losses and negative cash flows.
-
Q2 Net Loss of $16.5 Million
Net loss for the three months ended June 30, 2026 was $16.5 million, driven by a $9.8 million non-cash loss from warrant liability fair value changes and increased operating expenses.
-
Cash Runway into Q1 2027
Cash and cash equivalents totaled $26.7 million as of June 30, 2026, which management expects will fund drug development operations through at least the first quarter of 2027.
-
Kadima Acquisition Terminated
On August 12, 2026, HOPE and HTX terminated the Kadima Purchase Agreement for cause, alleging unmet closing conditions and breach of contract, with ongoing arbitration and litigation.
Analysis · NRXP · Life Sciences
The Q2 2026 10-Q from NRX Pharmaceuticals shows a $16.5 million quarterly net loss, a going concern warning, and a $9.8 million non-cash warrant liability charge. The company terminated its Kadima acquisition and disclosed DARPA selection for a $11.5 million trial. Cash stands at $26.7 million, funding operations into Q1 2027, but substantial doubt about its ability to continue as a going concern remains.
At the time of this filing, NRXP was trading at $3.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137.2M. The 52-week trading range was $1.62 to $5.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.